Kaelo Seatla

Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-naïve HIV-1 Subtype C-infected patients in Botswana.

Maruapula D, MacLeod IJ, Moyo S, Musonda R, Seatla K, Molebatsi K, Leteane M, Essex M, Gaseitsiwe S, Rowley CF.

AAS Open Res. 2020. 3:50. PMID: 34036243

HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana.

Seatla KK, Maruapula D, Choga WT, Ntsipe T, Mathiba N, Mogwele M, Kapanda M, Nkomo B, Ramaabya D, Makhema J, Mmalane M, Mine M, Kasvosve I, Lockman S, Moyo S, Gaseitsiwe S.

Viruses. 2021 03 31. 13(4). PMID: 33807382

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana.

Maseng MJ, Tawe L, Thami PK, Seatla KK, Moyo S, Martinelli A, Kasvosve I, Novitsky V, Essex M, Russo G, Gaseitsiwe S, Paganotti GM.

Pharmgenomics Pers Med. 2021. 14:335-347. PMID: 33758532

Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in Botswana.

Kelentse N, Moyo S, Mogwele M, Lechiile K, Moraka NO, Maruapula D, Seatla KK, Esele L, Molebatsi K, Leeme TB, Lawrence DS, Musonda R, Kasvosve I, Harrison TS, Jarvis JN, Gaseitsiwe S.

Medicine (Baltimore). 2020 Oct 09. 99(41):e22606. PMID: 33031315

In Silico Prediction of Human Leukocytes Antigen (HLA) Class II Binding Hepatitis B Virus (HBV) Peptides in Botswana.

Choga WT, Anderson M, Zumbika E, Phinius BB, Mbangiwa T, Bhebhe LN, Baruti K, Kimathi PO, Seatla KK, Musonda RM, Bell TG, Moyo S, Blackard JT, Gaseitsiwe S.

Viruses. 2020 07 06. 12(7). PMID: 32640609

Comparison of an in-house 'home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples.

Seatla KK, Choga WT, Mogwele M, Diphoko T, Maruapula D, Mupfumi L, Musonda RM, Rowley CF, Avalos A, Kasvosve I, Moyo S, Gaseitsiwe S.

PLoS One. 2019. 14(11):e0224292. PMID: 31751353

Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana.

Seatla KK, Avalos A, Moyo S, Mine M, Diphoko T, Mosepele M, Gaolatlhe T, Rowley CF, Ramaabya D, Jarvis JN, Kasvosve I, Gaseitsiwe S.

AIDS. 2018 08 24. 32(13):1899-1902. PMID: 29894383